About Multiple MyelomaMultiple myeloma is an incurable blood cancer with a five-year relative survival rate of approximately 41 percent, one of the lowest of all cancers. In 2012, an estimated 21,700 adults in the United States will be diagnosed with multiple myeloma and approximately 10,710 people will die from the disease. About MannKind Corporation MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZAR, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.